首页> 外文期刊>The Open Drug Discovery Journal >Erythropoietin Levels in Cardiac Resynchronization Patients
【24h】

Erythropoietin Levels in Cardiac Resynchronization Patients

机译:心脏再同步患者的促红细胞生成素水平

获取原文
           

摘要

Cardiac resynchronization therapy (CRT) is indicated in patients with advanced heart failure secondary tosevere systolic impairment and refractory symptoms despite optimized medical treatment and evidence of electromechanicaldyssynchrony with a QRS complex greater than 120 milliseconds (msec). Approximately 20%-30% ofpatients who receive CRT fail to respond with little improvement in subjective symptoms, functional capacity, and leftventricular indices. To date, there fails to be a serologic marker to adequately assess the degree of ventriculardyssynchrony and electro-mechanical dissociation. Increased levels of erythropoietin (EPO), a hematopoietic cytokine,has been demonstrated in patients with more advanced stages of heart failure and is associated with an increase inmortality and hospital re-admission. A recent study demonstrated a significant response to CRT in patients with higherbaseline EPO levels (> 25mU/mL) with improvements in cardiac function and reduced heart failure symptoms. Thepresence of elevated EPO levels in addition to traditional determinants of cardiac dyssynchrony may effectively predictthose that will benefit from CRT.
机译:尽管进行了优化的药物治疗和QRS复合波大于120毫秒(msec)的证据表明,心脏重同步治疗(CRT)适用于继发于严重收缩压和收缩期症状继发的严重心力衰竭的患者。接受CRT的患者中约有20%-30%的患者在主观症状,功能能力和左心室指标方面无明显改善。迄今为止,还没有血清学标记物可以充分评估心室不同步和机电分离的程度。在具有较严重心力衰竭的患者中,已经证实了造血细胞因子促红细胞生成素(EPO)水平的升高,并与死亡率增加和住院率增加有关。最近的一项研究表明,基线EPO水平较高(> 25mU / mL)的患者对CRT的反应显着,其心脏功能得到改善,心力衰竭症状减轻。除传统的心脏不同步因素外,EPO水平升高还可能有效预测那些将从CRT中受益的因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号